RPS14 (Ribosomal Protein S14) encodes an essential ribosomal protein component of the 40S small ribosomal subunit. RPS14 is one of the most frequently mutated ribosomal proteins in Diamond-Blackfan anemia (DBA), accounting for approximately 6% of cases, and is also commonly deleted in 5q deletion syndrome (5q- syndrome), a distinct form of myelodysplastic syndrome (MDS)[@boria2010][@ebert2010]. Beyond its well-established role in hematologic disorders, emerging evidence links ribosomal protein dysfunction to neurodegenerative diseases through mechanisms involving ribosomal stress response, p53 activation, and translational dysregulation[@de2024][@khincha2024].
| Full Name | Ribosomal Protein S14 |
|---|
| Gene Symbol | RPS14 |
|---|
| Chromosomal Location | 5q33.1 |
|---|
| NCBI Gene ID | 6208 |
|---|
| OMIM | 607652 |
|---|
| Ensembl ID | ENSG00000129864 |
|---|
| UniProt ID | P62277 |
|---|
| Protein Length | 151 amino acids |
|---|
| Protein Molecular Weight | ~16 kDa |
|---|
| Associated Diseases | [Diamond-Blackfan Anemia](/diseases/diamond-blackfan-anemia), [Myelodysplastic Syndrome](/diseases/myelodysplastic-syndrome), [5q Deletion Syndrome](/diseases/5q-deletion-syndrome) |
|---|
RPS14 is a component of the 40S ribosomal subunit, playing critical roles in ribosome assembly, translational initiation, and cellular homeostasis. The 40S subunit, together with the 60S large subunit, forms the complete 80S ribosome responsible for protein synthesis in eukaryotic cells[@mills2017].
RPS14 is located at the interface of the 40S subunit, where it contributes to:
- rRNA binding and stabilization: RPS14 interacts with 18S rRNA, stabilizing the rRNA structure
- mRNA binding: The protein participates in the mRNA entry channel, facilitating mRNA binding and scanning
- Translation initiation: RPS14 contributes to the formation of the pre-initiation complex (43S PIC)
- Small subunit assembly: Proper RPS14 incorporation is essential for 40S biogenesis
When ribosomal function is compromised, cells activate a conserved "ribosomal stress response" that involves:
- Free ribosomal protein accumulation: Unassembled ribosomal proteins accumulate in the nucleus
- p53 activation: Certain ribosomal proteins (including RPS14) can bind to MDM2, releasing p53 from MDM2-mediated degradation
- Cell cycle arrest: p53 activation leads to p21-mediated cell cycle arrest
- Apoptosis: Sustained ribosomal stress can trigger apoptotic pathways
This ribosomal stress response is particularly relevant to neurodegeneration, as neurons are highly dependent on precise translational control for synaptic function and plasticity[@de2024].
RPS14 was the sixth ribosomal protein gene identified as causing DBA, following the discovery that heterozygous mutations in RPS14 cause a specific subset of Diamond-Blackfan anemia characterized by macrocytic anemia and increased risk of certain solid tumors[@gazda2008][@flygare2011].
Mechanism of DBA in RPS14 mutation:
- Haploinsufficiency: Most pathogenic RPS14 variants create null alleles, leading to reduced RPS14 protein levels
- Impaired ribosome biogenesis: Reduced RPS14 availability compromises 40S ribosomal subunit assembly
- Selective translational defect: Erythroid progenitor cells are particularly sensitive to ribosomal stress due to high translational demands
- p53 activation: Ribosomal stress activates p53, leading to apoptosis of erythroid precursors
RPS14 is one of several genes within the commonly deleted region of chromosome 5q that contributes to the 5q- syndrome phenotype. This syndrome is characterized by macrocytic anemia, normal platelet count (or thrombocytosis), and predisposition to acute myeloid leukemia (AML)[@boultwood2022][@warner2023].
The "RPS14 haploinsufficiency model" for 5q- syndrome demonstrates that:
- Heterozygous deletion of RPS14 is sufficient to cause the characteristic cytopenia
- RPS14 haploinsufficiency creates ribosomal stress leading to p53 activation
- The p53-dependent response selectively affects hematopoietic stem/progenitor cells
- Combined deletion of RPS14 with other commonly deleted genes (including MAP3K7 and CTC1) modifies the phenotype
While RPS14 is not directly implicated in neurodegenerative diseases, the ribosomal dysfunction seen in RPS14-related disorders provides insight into mechanisms relevant to neurodegeneration[@de2024]:
Translational Dysregulation in Neurodegeneration:
- Many neurodegenerative diseases (Alzheimer's, Parkinson's, ALS) feature impaired protein synthesis
- Ribosomal protein mutations may sensitize neurons to additional cellular stress
- The ribosomal stress response pathway (p53 activation) is dysregulated in several neurodegenerative conditions
p53 and Neurodegeneration:
- p53 activation in neurons can lead to apoptosis
- Chronic low-level ribosomal stress may contribute to neuronal loss
- Ribosomal protein haploinsufficiency may accelerate neurodegeneration in predisposed individuals
Ribosomopathies and Neurological Phenotypes:
- Some ribosomopathy patients exhibit neurodevelopmental delays
- The connection between ribosomal function and neurological outcomes is an emerging area of research
RPS14 is a small, basic ribosomal protein with the following structural features:
- α-helical structure: RPS14 contains multiple α-helical domains
- rRNA binding interface: The protein interacts with 18S rRNA through multiple regions
- Surface accessibility: Regions of RPS14 are exposed on the surface of the 40S subunit, available for interactions with other proteins
The crystal structure of the 40S ribosomal subunit has revealed RPS14's position at the subunit interface, where it contributes to both intersubunit contacts and mRNA channel formation.
Understanding RPS14 function has therapeutic implications for several conditions:
Current and emerging therapeutic approaches include:
- Corticosteroids: First-line therapy for DBA, working through unknown mechanisms
- L-leucine: Amino acid that can improve translation efficiency; showing promise in clinical trials
- Gene therapy: Autologous hematopoietic stem cell gene addition approaches
- Small molecule activators: Development of compounds that enhance residual ribosomal function
For 5q- syndrome:
- Lenalidomide: Highly effective in 5q- MDS, though mechanisms involve different genes
- Hypomethylating agents: Azacitidine and decitabine in higher-risk MDS
- Allogeneic stem cell transplantation: Curative option for eligible patients
Ribosomal biology insights inform:
- mTOR inhibitors: Modulate translation to reduce ribosomal stress
- p53 modulators: Targeting downstream effects of ribosomal stress
- Translation enhancers: Supporting healthy protein synthesis in neurons
¶ Mermaid Diagram: RPS14 in Ribosomal Function and Disease
flowchart TD
subgraph Ribosome_Biogenesis
A["RPS14 Gene<br/>Transcription"] --> B["mRNA<br/>Translation"]
B --> C["RPS14 Protein<br/>Synthesis"]
C --> D["40S Subunit<br/>Assembly"]
D --> E["80S Ribosome<br/>Formation"]
end
subgraph Normal_Function
E --> F["Cap-Dependent<br/>Translation"]
F --> G["Protein<br/>Synthesis"]
G --> H["Cell<br/>Proliferation"]
end
subgraph Disease_States
I["RPS14 Mutation<br/>or Deletion"] --> J["Ribosomal<br/>Stress"]
J --> K["MDM2<br/>Inhibition"]
K --> L["p53<br/>Activation"]
L --> M["Cell Cycle<br/>Arrest / Apoptosis"]
I --> N["40S Biogenesis<br/>Defect"]
N --> O["Impaired<br/>Translation"]
O --> P["Selective<br/>Cytopenia"]
end
subgraph Neurodegeneration_Connection
J --> Q["Chronic<br/>Ribosomal Stress"]
Q --> R["Translational<br/>Dysregulation"]
R --> S["Neuronal<br/>Dysfunction"]
S --> T["Synaptic<br/>Impairment"]
end
style I fill:#ffcdd2
style P fill:#ffcdd2
style T fill:#ffcdd2
style M fill:#ef9a9a
- Gazda et al., Frameshift mutation in RPS14 causes DBA (2008)
- Boria et al., Ribosomal basis of DBA (2010)
- Narla & Ebert, Ribosomopathies (2010)
- Mills & Green, Ribosomopathies: strength in numbers (2017)
- Warner et al., RPS14 and 5q- syndrome (2023)
- De Keersmaecker et al., Ribosomal proteins in MDS/AML and neurodegeneration (2024)
- Yelick & Trainor, Ribosomopathies and developmental cascade (2020)
- Boultwood et al., 5q- syndrome and ribosomal proteins (2022)
- Ebert et al., RPS14 deficiency and p53-dependent cytopenia (2010)
- Flygare & Karlsson, DBA erythropoiesis gone awry (2011)
- Ulirsch et al., Genetic landscape of DBA (2018)
- Khincha & Savage, Ribosomopathies overview (2024)
- De Keersmaecker et al., Ribosomal proteins as tumor suppressors (2015)
- Wang et al., Ribosomal protein mutations in MDS (2018)